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Edited by Ned ManteiAbstract Fas ligand (FasL) binds Fas (CD95) to induce apop-
tosis or activate other signaling pathways. In addition, FasL
transduces bidirectional or ‘reverse signals’. The intracellular do-
main of FasL contains consensus sequences for phosphorylation
and an extended proline rich region, which regulate its surface
expression through undetermined mechanism(s). Here, we used
a proteomics approach to identify novel FasL interacting pro-
teins in Schwann cells to investigate signaling through and traf-
ﬁcking of this protein in the nervous system. We identiﬁed two
novel FasL interacting proteins, sorting nexin 18 and adaptin
b, as well as two proteins previously identiﬁed as FasL interact-
ing proteins in T cells, PACSIN2 and PACSIN3. These proteins
are all associated with endocytosis and traﬃcking, highlighting
the tight regulation of cell surface expression of FasL in the ner-
vous system.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Fas ligand (FasL, CD95L, CD178), a member of the tumor
necrosis factor (TNF) superfamily, is a type II, homotrimeric
protein with cell surface and secreted isoforms. FasL is induc-
ibly expressed by cells of the immune system upon activation
and in the nervous system after injury, and is constitutively ex-
pressed in ‘‘immune privileged’’ tissues, such as the eye and
reproductive system [1,2]. Traditionally, FasL has been viewed
exclusively as a ligand for the Fas receptor, stimulating forma-Abbreviations: AICD, activation induced cell death; DISC, death
inducing signaling complex; SH3, Src homology 3; ICD, intracellular
domain; LC-MSMS, liquid chromatography coupled tandem mass
spectrometry; IRES, internal ribosomal entry site; GST, glutathione-S-
transferase; PX, Phox homology domain; CC, coiled coil domain;
MAPK, mitogen activated protein kinase; ERK, extracellular-signal
regulated kinase; AP, adaptor protein; EGFP, enhanced green
ﬂuorescent protein; TNF, tumor necrosis factor
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doi:10.1016/j.febslet.2007.08.025tion of a death inducing signaling complex (DISC) and activa-
tion of a caspase cascade, ultimately culminating in apoptosis
[3]. The apoptotic eﬀector function of FasL is particularly well
documented in the immune system, where FasL is an eﬀector
of activation induced lymphocyte cell death (AICD), and of
target cell killing by cytotoxic T lymphocytes [4]. In addition
to the eﬀector function of FasL as a ligand for Fas, increasing
evidence has suggested that FasL and other membrane-bound
TNF superfamily ligands can also transduce ‘‘reverse signals’’
and thus participate in bidirectional signaling [5].
The FasL intracellular domain (ICD) contains a modular
architecture consistent with its role as a signal transducing
molecule. It contains a 26 amino acid proline rich region which
interacts with multiple Src homology 3 (SH3) and WW do-
main containing proteins in T cells, including several members
of the Src tyrosine kinase family [6,7]. In T cells, stimulation of
FasL with agonistic antibodies or Fas fusion proteins increases
its association with speciﬁc SH3 domain containing proteins
and results in activation of the extracellular-signal regulated
kinase (ERK) mitogen activated protein kinase (MAPK) path-
way [8,9]. In addition to its potential role in signal transduc-
tion, the FasL proline rich region has also been implicated in
sorting of the molecule to diﬀerent cellular compartments
[10], which may be important for regulating both FasL eﬀector
and reverse signaling activities. The FasL ICD also contains a
conserved, cytosolic casein kinase I (CKI) motif, SXXS, that
has been implicated in reverse signaling in other TNF family
members [5,11]. Recently, Sun et al. have documented changes
in FasL serine phosphorylation following treatment of cul-
tured cells with a Fas fusion protein [9].
Although FasL has been extensively studied in the immune
system, FasL traﬃcking and reverse signaling have never been
studied in the nervous system. FasL expression is induced on
nervous system glial cells, including Schwann cells, following
injury [12]. Fas is also expressed in the nervous system and is
upregulated after injury, suggesting that Fas/FasL interactions
may play a role in the injured nervous system [13]. We have
previously found that expression of Fas and FasL inﬂuenced
peripheral nerve regeneration after crush injury [14].
Here, we used a proteomic approach to identify novel FasL
interacting proteins in Schwann cells, the glial cells of the
peripheral nervous system, to gain insight into mechanisms
of reverse signaling and traﬃcking of FasL in the nervous sys-
tem. Using liquid chromatography-tandem mass spectrometryblished by Elsevier B.V. All rights reserved.
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ing proteins, we identiﬁed Sorting Nexin 18 (SNX18), adaptin
b, Protein Kinase C and Casein Kinase Substrate in Neurons 2
(PACSIN2), and PACSIN3 as FasL interacting proteins. The
binding of FasL to multiple proteins implicated in traﬃcking
suggests tight regulation of the reverse signaling and eﬀector
functions of FasL within the nervous system.2. Materials and methods
2.1. Cells
Mouse Schwann cells were isolated from sciatic nerves of neonatal
(P1 to P3) C3H/HeJ mice. Nerves were digested in collagenase (Sigma)
then in trypsin/DNase (Worthington Biochemicals). Cells were grown
in DMEM plus 10% fetal calf serum (FCS, Hyclone), 100 U/ml peni-
cillin, 100 lg/ml streptomycin (Gibco), 0.1 mM non-essential amino
acids (Gibco), and 10 lM cytosine-b-D-arabinofuranoside (Ara-C,
Sigma). Schwann cell cultures were treated with anti-mouse Thy1.2
(CD90.2) antibody-containing supernatant derived from the HO-13-4
hybridoma (American Type Culture Collection) and rabbit LowTox
complement (Cedarlane) to remove residual ﬁbroblasts. To verify the
purity of the cultures, cells were examined using ﬂow cytometry as
follows: cells were trypsinized from cell culture plates, then either
permeabilized and stained using the Cytoﬁx/Cytoperm ﬁxation/
permeabilization solution kit (BD Biosciences) for intracellular pro-
teins according to the manufacturer’s recommendations, or stained
in PBS/2% FCS for surface markers. Labelling was performed on ice
for 25 min with the indicated primary antibodies or isotype control
antibodies. After two wash cycles all samples were stained with phyco-
erythrin conjugated secondary antibodies. Cells were washed twice
more and analyzed using a FACSAria cell analyzer (BD Biosci-
ences).2.2. Construction of FasL deletion mutants
Human Fas Ligand (huFasL) cDNA was purchased from Open
Biosystems. FasL deletion mutants, HuFasLD 2–33-FLAG and
HuFasLD2–70-FLAG, were created using wild-type FasL cDNA as
a template to produce PCR products missing base pairs corresponding
to N-terminal amino acids 2–33 and 2–70, respectively, but still con-
taining the initiator methionine (AUG) base pairs. The huFasL and
huFasLD2–33 coding sequences were PCR ampliﬁed using forward
primers 5 0-CACCTGCAGCCATGCAGC-30 and 5 0-GGGCTGC-
AGCCATGACCTCTGTGCCCAGAAGGC-3 0, respectively, paired
with the reverse 5 0-CTCTTAAAGCTTATATAAGCCG-3 0 primer
and PFUltra DNA polymerase (Stratagene). The resulting PCR
products were cloned in frame into pCMV-Tag4A (Stratagene) with
PstI (Invitrogen) and HindIII (New England Biolabs) to generate
C-terminal FLAG tagged proteins. HuFasL-FLAG and huFasLD
2–33-FLAG were then excised with PstI and Acc65I (Fermentas),
and subcloned into the pIRES2-EGFP (Clontech) SmaI (New England
Biolabs) site after ﬁll-in reactions using the Klenow fragment (Invitro-
gen). HuFasLD 2-70-FLAG was created by PCR ampliﬁcation
with primers 5 0-GGGCTGCAGCCATGCTGAAGAAGAGAGGG-
AACCACAGC-3 0 (forward) and 5 0-CTACTTATCGTCGTCAT-
CCTTG-30 (reverse) using huFasL-FLAG as a template and cloned
into the pIRES2-EGFP SmaI site. All vectors were fully sequenced
before transfecting into cells to ensure the absence of mutations/frame-
shifts created during PCR ampliﬁcation.2.3. Creation of stably transfected cell lines
Mouse Schwann cells were transfected with huFasL-FLAG,
huFasLD2-33-FLAG, huFasLD2-70-FLAG, or empty pIRES2-EGFP
vector as a control using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s recommendations. EGFP positive cells were sin-
gle cell sorted into 96 well plates using a FACSAria ﬂuorescence acti-
vated cell sorter (BD Biosciences). Cells were expanded in DMEM
with 10% FCS, 0.1 mM non-essential amino acids, 1 mM sodium pyru-
vate (Gibco) and 400 lg/ml G418 (Wisent Bioproducts). Clones were
screened for expression of FasL constructs and EGFP by immunoblot-
ting cellular lysates.2.4. RNA extraction and RT-PCR
RNA extraction was performed on 2 · 105 cells using the Charge-
Switch total RNA kit (Invitrogen) according to the manufacturer’s
instructions. RNA was quantiﬁed using the Quant-iT Ribogreen
RNA assay kit (Invitrogen) according to the manufacturer’s protocol.
Reverse transcription reactions were primed with 5 lM random
decamers (Ambion), and ampliﬁed with 4U Sensicript reverse
transcriptase (Qiagen). Primers for PCR ampliﬁcation were as
follows: 18S rRNA sense: 5 0TGAGAAACGGCTACCACATCC30,
18S rRNA antisense: 5 0TCGCTCTGGTCCGTCTTGC3 0, FasL
sense: 5 0CTGGTTGCCTTGGTAGGATTGGG3 0, FasL antisense:
5 0GGACCTTGAGTTGGACTTGCCTG3 0, EGFP sense: 5 0GCCAC-
AAGTTCAGCGTGCTCG3 0, EGFP antisense: 5 0TCTTCTGCTTG-
TCGGCCATGATAT3 0 (Invitrogen). PCR reactions were performed
using HotstarTaq (Qiagen) in a Techne Touchgene Gradient thermo-
cycler as follows: 18S rRNA: 15 min at 95 C, cycled 13 · 60 s at
94 C, 40 s at 66.2 C, 30 s at 72 C, then ﬁnal elongation 10 min at
72 C. EGFP and FasL: 15 min at 95 C, cycled 25 · 60 s at 94 C,
20 s at 65.2 C, 40 s at 72 C, then ﬁnal elongation 10 min at 72 C.
PCR products were visualized on 1.2% agarose gel (Invitrogen).2.5. Immunoprecipitation (IP) and immunoblotting
For IP, mouse Schwann cells were lysed in buﬀer containing 0.5%
Nonidet P-40 (Bioshop Canada), 25 mM HEPES, pH 7.4, 115 mM
potassium acetate, 5 mM magnesium chloride, 1 mM sodium ortho-
vanadate (all from Sigma), and Complete Mini protease inhibitor
cocktail (Roche). Lysates remained on ice for 15 min before centrifuga-
tion at 15000 rpm for 10 min at 4 C. Supernatants were then pre-
cleared against unconjugated Sepharose 4B (Sigma) for 1.5 h at 4 C.
For validation experiments, supernatants were precleared with Protein
G-Sepharose and isotype control antibodies. Beads were then pelleted,
and precleared supernatants were incubated for at least 2 h at 4 C
with anti-FLAG or isotype control antibodies (Sigma) covalently
cross-linked to Protein G-Sepharose (GE Healthcare) using dimethyl
pimelimidate (Sigma). The beads were pelleted, washed three times
in cold lysis buﬀer, boiled in Laemli buﬀer containing b-mercap-
toethanol, and electrophoresed on SDS–polyacrylamide gels. SDS gels
were then either transferred to polyvinylidene diﬂuoride membranes
(PVDF, BioRad) and subjected to immunoblotting or stained with
colloidal Coomassie blue (Invitrogen) followed by tandem mass
spectrometry of selected gel bands. PVDF membranes were blocked
overnight at 4 C in 5% non-fat dry milk powder (w/v) in Tris-buﬀered
saline/0.1% Tween 20 (Fisher Scientiﬁc, TBST) and blotted with the
indicated primary antibody and horseradish peroxidase (HRP)-conju-
gated secondary antibodies. Bands were visualized using ECL PLUS
reagents (GE Healthcare) and ﬁlm from Molecular Technologies Inc.2.6. Mass spectrometry of selected gel bands
Coomassie stained gel bands detected at higher intensity in the
FLAG IP than in the isotype control IP were excised and minced man-
ually with a scalpel, washed with water and dehydrated in acetonitrile
(Sigma-Aldrich). The corresponding gel area in the isotype control lane
was also excised for mass spectrometric analysis to separate legitimate
interacting proteins from those highly prevalent at the same molecular
weight. Gel pieces were spun down and dried using a vacuum centri-
fuge, followed by reduction in 10 mM dithiotreitol/0.1 M ammonium
bicarbonate (Sigma-Aldrich), alkylation in 55 mM iodoacetamide (Sig-
ma-Aldrich)/0.1 M ammonium bicarbonate, followed by extensive
washing in 1:1 (v/v) 0.1 M ammonium bicarbonate/acetonitrile to
remove residual Coomassie stain. Digestion was performed with
12.5 ng/ll trypsin (Promega) in 50 mM ammonium bicarbonate,
5 mM calcium chloride (Sigma-Aldrich). Peptides remaining in the
gel were then extracted twice in 1:1 (v/v) 25 mM ammonium bicarbon-
ate/acetonitrile and 1:1 (v/v) 5% formic acid/acetonitrile, respectively.
Extracted samples were pooled and dried using a vacuum centrifuge
for mass spectrometry at the Institute for Research in Immunology
and Cancer proteomic center at the Universite´ de Montre´al. The dried
peptides were resuspended in 5 ll of 0.2% formic acid and injected on a
NanoACQUITY HPLC system (Waters Limite´e). Peptides were ﬁrst
trapped by a reversed phase C18 precolumn (300 lm i.d. · 5 mm
length) and subsequently separated on a C18 analytical column
(150 lm i.d. · 10 cm, particle size 3 lm). NanoLC separation was
achieved using a 56-min linear gradient from 5% to 60% aqueous ace-
tonitrile (0.2% FA) at a ﬂow rate of 600 nl/min. Mass spectrometric
P.B. Thornhill et al. / FEBS Letters 581 (2007) 4455–4462 4457acquisitions in the MS/MS mode were performed on a Q-TOF Premier
instrument (Waters Limite´e). Database searches were performed
against the NCBI non-redundant protein database using Mascot soft-
ware (http://www.matrixscience.com). We used the following criteria
to deﬁne potentially valid protein hits (Table 1): protein hits were sup-
ported by at least 2 peptides and had a predicted molecular weight
within 10 kDa of the excised gel band. Proteins with peptide hits
present in the isotype background band were excluded from further
analysis, as well as hits for antibody fragments, trypsin, and/or other
highly prevalent cellular proteins known to non-speciﬁcally precipitate
in IP experiments.
2.7. Generation of GST-SNX18 SH3 domain and peptide spots array
synthesis
Wild-type SH3 domain SNX18 cDNA was subcloned into
pGEX3X-4T1 (Amersham Pharmacia Biotech) expression vector by
PCR and its sequence was veriﬁed. To isolate recombinant protein,
GST-fusion constructs were expressed in BL21-Codon Plus RP cells
(Stratagene) and induced with 0.1 M isopropyl-b-D-thiogalactopyra-
noside (IPTG) for 3 h at 18 C. Bacterial pellets were resuspended in
100 mM potassium phosphate buﬀer and sonicated. Lysate was then
cleared by centrifugation at 35000 · g and recombinant GST-fusion
protein was isolated using Glutathione Sepharose 4 Fast Flow (Amer-
sham Pharmacia Biotech) and eluted with 50 mM reduced glutathione
(Sigma) in 50 mM Tris, pH 8.5.
Peptide arrays were produced according to the spots-synthesis meth-
od [15]. Acid-hardened cellulose membranes prederivatized with a
polyethylene glycol spacer (Intavis AG, Cologne, Germany) and stan-
dard 9-ﬂuorenylmethoxy carbonyl (Fmoc) chemistry was used for syn-
thesis. Fmoc-protected and activated amino acids (Intavis) were
spotted in high-density 20 · 30 arrays on 150- by 100-mm membranes
using an Intavis MultiPep robot. Membranes were blocked overnight
in 5% skim milk, incubated with 1 lM puriﬁed GST fusion proteins
in TBST for 3 h at 4 C, washed three times, and probed with mouse
monoclonal anti-GST HRP-conjugated antibody (Santa Cruz) fol-
lowed by enhanced chemiluminescence detection (Pierce).
2.8. Antibodies
For IP, monoclonal anti-FLAG M2 (Sigma) or mouse IgG1 control
(Sigma) antibodies were used. Anti-FasL (cloneG247.4, BD Biosci-
ences) or anti-adaptin b (BD Biosciences) were used for the detection
of immunoprecipitated proteins in immunoblots. EGFP was detected
using clone JL-8 (Clontech). Anti-SNX18 antisera were generated by
immunizing rabbits with a KLH-conjugated GFKKEYQKVGQSFR
peptide (500 lg) in Freund’s Complete Adjuvant and boosting twoTable 1
LC-MSMS proteins ‘‘Hits’’ co-precipitated with human FasLD33 in murine
Protein name(s) Band MW Predicted
MW
# of Unique
peptides
Seq
Cov
Fas ligand 35 kDa 37 kDa 5 20%
Protein kinase C and casein
kinase substrate in neurons
3(PACSIN3);Syndapin 3
52 kDa 48 kDa 2 4%
Protein kinase C and casein
kinase substrate in neurons 2
(PACSIN2); Syndapin 2
60 kDa 56 kDa 12 30%
Sorting nexin associated
golgi protein 1;
Sorting Nexin 18
71 kDa 68 kDa 9 18%
Sorting nexin associated
golgi protein 1;
Sorting Nexin 18
74 kDa 68 kDa 3 7%
Beta adaptin subunit 110 kDa 98 kDa 2 5%times with peptide (100 lg) in Freund’s Incomplete Adjuvant. For ﬂow
cytometric detection, anti-S100 (Chemicon), anti-GFAP (BD Biosci-
ences), or anti-Thy1.2-PE (BD Biosciences) were used and compared
to isotype control antibodies mouse IgG2a (BD Biosciences), mouse
IgG2b (Sigma), and rat IgG2a-PE (BD Biosciences), respectively.3. Results
3.1. Stable expression of FasL constructs in Schwann cell lines
To investigate the proteins associated with FasL within the
nervous system, we ﬁrst created stable Schwann cell transfec-
tants expressing wild-type or truncated FasL constructs.
Schwann cells isolated from mouse sciatic nerve which sponta-
neously became transformed in cell culture were used for the
establishment of stable transfectants. These cells expressed
the Schwann cell markers S100 and glial ﬁbrillary acidic pro-
tein (GFAP), but not the ﬁbroblast marker Thy1.2 (Fig. 1A).
Wild-type FasL-FLAG (wtFasL), FasL-FLAG lacking amino
acids 2–33 (FasLD2–33), which include the casein kinase con-
sensus sequence, and FasL-FLAG lacking amino acids 2–70
(FasLD2–70), which encode the proline rich domain
(Fig. 1B), were stably expressed in Schwann cells in conjunc-
tion with the enhanced green ﬂuorescent protein (EGFP),
using a bicistronic approach. The bicistronic vector, pIRES2,
contains an internal ribosomal entry site (IRES) upstream of
the EGFP gene, resulting in co-translational expression of
FasL and EGFP on the same mRNA. As expected, the ratio
of FasL to EGFP mRNA was similar for all three FasL con-
structs (Fig. 1C). However, we noticed substantial diﬀerences
in the ratios of FasL to EGFP protein expression between
the diﬀerent FasL constructs (Fig. 1D). While wtFasL was
expressed at very low levels compared to EGFP, the ratio of
FasLD2–33 to EGFP was roughly 10-fold higher. The expres-
sion ratio of FasLD2–70 to EGFP was also increased 6-fold
relative to wtFasL. Our results suggest that truncations in
the coding region of FasL do not alter the transcriptional eﬃ-
ciency of FasL with respect to EGFP, but may increase theSchwann cells
uence
erage
UniProt
accession #
Matched peptides
gij2168140 ELAELR, QIGHPSPPPEK,
GQSNNLPLSHK, ESTSQMHTASSLEK,
MMSYCTTGQMWAR,
gij11127644 GPQYGTLEK, TQYEQTLAELNR
gij19483913 EVLLEVQK, AADAVEDLR, GPQYGTVEK,
VSELHLEVK, ASLMNEDFEK,
ADPSLNPEQLK, HLDLSNVASYK,
AWIAVMSEAER, IEDEDEQGWK,
LGDLMNLHER, ALYDYEGQEHDELSFK,
ANHGPGMAMNWPQFE- EWSADLNR
gij26342577 ALYDFK, SDLSLGSR, FEEDFISK,
SENPGEISLR, GLFPASYVQVIR,
APEPGPPADGGPGAPAR,
SGGEAFVLGEASGFVK,
SQMQHFLQQQIIFFQK,
KMDDSALQLNHTANEFAR
gij26342577 GLFPASYVQVIR,
APEPGPPADGGPGAPAR,
SGGEAFVLGEASGFVK
gij51701351 EYATEVDVDFVR, LASQANIAQVLAELK
Fig. 1. FasL deletion mutants are expressed more eﬃciently than wild-type FasL. (A) The Schwann cell line used in our proteomic screen expresses
GFAP and S100, but not Thy1.2, as detected by ﬂow cytometry. Dotted lines show background control staining and solid lines represent staining for
GFAP, S100, or Thy1.2. (B) The 80 amino acid FasL intracellular domain is shown in biochemical single letter code. Sites of truncation for FasL
constructs (D33, D70), the proline rich region, and casein kinase phosphorylation consensus are indicated. (C) Stably transfected Schwann cell clones
expressing bicistronic wild-type (Wt) or truncated FasL-IRES-EGFP constructs were analysed for expression of FasL. FasL and EGFP mRNA, as
well as 18S rRNA, were ampliﬁed by RT-PCR to examine the relative expression of FasL and EGFP message. Densitometric values were normalized
to 18S rRNA to control for loading diﬀerences. Graphs show the ratios of FasL to EGFP mRNA for each construct. (D) Lysates from Schwann cells
expressing Wt and truncated FasL were simultaneously immunoblotted for FasL and EGFP. Graphs show the densitometric ratios of FasL to EGFP
protein expression for each construct. Blots and ratios are representative of multiple Schwann cell clones expressing each construct.
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cells. Previous reports have documented increased translation
and decreased cytotoxicity of FasL constructs after deletion
of the intracellular region of FasL [16,17]. It is therefore
possible that the dramatically greater expression of the FasL
deletion mutants compared to the wtFasL protein may be
attributed to increased translational eﬃciency and/or de-
creased cytotoxicity of the truncated forms of FasL.3.2. Screen for FasL interacting proteins in Schwann cells
We used Schwann cells expressing FasLD2–33 for our screen
due to the poor expression of wtFasL (Fig. 1D), and because
previous screens in T cells did not detect proteins able to inter-
act with GST-FasL2–29 [6]. We employed a co-immunoprecip-
itation (co-IP) approach to identify FasL interacting proteins
in lysates from Schwann cells expressing FLAG-tagged
FasLD2–33. When IPs were run on gel and stained with colloi-
dal Coomassie, six bands at approximately 37, 52, 60, 71, 74and 110 kDa were uniquely present or greatly increased in
anti-FLAG IPs versus control IgG IPs (Fig. 2). Using LC-
MSMS, we identiﬁed these proteins as FasL, Protein Kinase
C and casein kinase substrate in Neurons 2 (PACSIN2; Synda-
pin2), PACSIN3/Syndapin3, Sorting Nexin Associated Golgi
protein 1 (SNAG1; Sorting Nexin 18; SNX18 – present in
two bands at 71 and 74 kDa), and adaptin b, respectively (Ta-
ble 1). Of the proteins identiﬁed, the SH3 domain-containing
adaptor proteins PACSIN2 and 3 have been previously
reported to interact with the proline rich region of FasL in T
cells, validating our screen and suggesting that these two inter-
actions are conserved in multiple cell types [6].3.3. Validation of FasL interaction with adaptin b
We proceeded to validate the novel interactions detected in
our screen by immunoblotting FasL IPs prepared from
Schwann cells stably expressing FasLD2–33 and FasLD2–70.
Antibodies to adaptin b detected a band at approximately
Fig. 2. Six bands are speciﬁcally co-immunoprecipitated by FLAG
antibodies in FasLD2–33-FLAG transfected Schwann cells FLAG-
tagged human FasLD2–33 was immunoprecipitated from stably
transfected Schwann cells using antibodies to FLAG, run on 4–20%
gradient SDS–PAGE, and stained with colloidal Coomassie Blue. Six
bands at 37, 52, 60, 71, 74 and 110 kDa were uniquely present or
greatly increased in anti-FLAG IPs versus control IgG IPs (arrows).
These bands and the corresponding gel regions from the control IPs
were excised for identiﬁcation using LC-MSMS.
Fig. 3. Adaptin b co-precipitates with FasL. (A) Lysates from
Schwann cells expressing FasLD2–33 or FasLD2–70 were immuno-
precipitated using control or FLAG antibodies and subjected to
immunoblotting for FasL and adaptin b. Co-precipitation of adaptin b
with both FasLD2–33 and FasLD2–70 indicates that the FasL proline
rich region is not necessary for this interaction. (B) Lysates from
Schwann cells expressing FasLD2–33 or FasLD2–70 were immuno-
precipitated as above and blotted for adaptin a or adaptin c. Bands
present in the lysate lanes indicate appropriate recognition of the
respective proteins in the immunoblot, although co-precipitation with
FasL was not detected. (C) Lysates from Schwann cells transiently
transfected with Wt FasL-FLAG were immunoprecipitated using
control or FLAG antibodies. Adaptin b was enriched in the FLAG co-
IP despite extremely low expression levels of Wt FasL.
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(Fig. 3A), indicating that the proline rich region of FasL was
not necessary for this interaction. Unsurprisingly, adaptin b
contains no proline binding motifs, although it contains an
appendage domain that interacts directly with clathrin
in vitro [18]. b adaptins make up one of the two large subunits
present in each of the heterotetrameric adaptor protein (AP)
complexes that bind ‘cargo’ proteins and facilitate the forma-
tion of clathrin coated vesicles [19]. Each of these heterotetra-
meric AP complexes possesses a unique subunit composition:
b1 is present with c adaptin in the AP-1 complex, and b2 with
a adaptin in the AP-2 complex. We sought to distinguish
which AP complex bound to FasL using antibodies to these
unique subunits. Although appropriate bands were observed
in cell lysates with antibodies to c and a adaptins, no corre-
sponding bands were detected in control or FasL IPs
(Fig. 3B). To ensure that the interaction of FasL with adaptin
b was legitimate and not an artifact due to FasL truncation, we
transiently transfected mouse Schwann cells with wild-type
FasL-FLAG and immunoblotted the co-IP products for b
adaptin (Fig. 3C). Although wild-type FasL is very poorly
expressed even during transient transfections, we observed a
speciﬁc enrichment of b adaptin in co-IPs performed with
anti-FLAG compared with isotype control antibodies.
3.4. Validation of FasL interaction with SNX18
Sorting Nexins are a family of 30 proteins involved in endo-
cytosis and protein traﬃcking. This protein family is character-
ized by the presence of a Phox (PX) domain, which binds
various phosphatidylinositol phosphates, targeting the pro-teins to cellular membranes. SNX18 contains an amino termi-
nal SH3 domain, a PX domain, and a carboxyl terminal coiled
coil (CC) domain. As no antisera to SNX18 were available to
validate the interaction with FasL, we immunized rabbits with
SNX18-derived peptides conjugated to Keyhole Limpet
Hemocyanin. The resulting antisera reproducibly recognized
a protein band of approximately 50 kDa and multiple bands
of 68–74 kDa in Schwann cells (Fig. 4) and mouse tissues (data
not shown). In agreement with our mass spectrometric data
(Table 1), an antisera-reactive band of approximately 74 kDa
co-precipitated with FasLD2–33, but not with FasLD2–70.
An additional band at approximately 50 kD, not detected in
our screen, also co-precipitated speciﬁcally with FasLD2–33.
The inability of FasLD2–70 to co-precipitate signiﬁcant
amounts of either band suggests that the binding of SNX18
to FasL requires an intact proline rich region, and may there-
fore be mediated by the SH3 domain of SNX18.
Fig. 4. SNX18 co-precipitates with FasL. Lysates from Schwann cells
expressing FasLD2–33 or FasLD2–70 were immunoprecipitated using
control or FLAG antibodies and subjected to immunoblotting with
antibodies to FasL and antiserum to SNX18. Bands at 74 and 50 kDa
(arrows) co-precipitated with FasLD2–33, but not with FasLD2-70,
suggesting that the proline rich region of FasL is necessary for this
interaction.
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SNX18
To determine whether FasL could interact directly with the
SH3 domain of SNX18, we investigated whether peptides cor-
responding to FasL 1–12, 18–29, 33–44, 61–72, and 130–141
could bind to an SNX18-SH3 construct fused to GST. We
found that FasL 33–44 and 61–72 speciﬁcally bound SNX18-
SH3-GST (Fig. 5A). These peptides both contain portions of
the FasL proline-rich domain, which supports a direct associ-
ation between the FasL proline-rich domain and the SH3
domain of SNX18. In contrast, peptide 130–141 did not bind
SNX18-SH3, consistent with the lack of speciﬁc binding of
FasLD2–70 to SNX18 (Fig. 4). Finally, peptides 1–12 and
18–29, which were absent in the truncated FasLD2–33, also
showed no speciﬁc binding to SNX18-GST. To conﬁrm that
wild-type FasL could interact with SNX18, we transiently
transfected Schwann cells with wild-type FasL-FLAG, andFig. 5. Peptides from the FasL proline-rich domain interact with the SNX18
61–72, and 130–141 were spotted onto an array and incubated with the SNX1
from the FasL proline rich region interacted with the SNX18 SH3 domain. (B
human FasL-FLAG were immunoprecipitated using control IgG or FLAG an
antiserum to SNX18. The band corresponding to the 50 kDa isoform of SNX
74 kDa (top arrow) is undetectable in this co-IP, this may be due to the extr
lane.immunoblotted the co-IP products for SNX18. Although
wild-type FasL is expressed far less eﬃciently than FasLD2–
33 (Fig. 1D), we conﬁrmed the interaction of wild-type FasL
with the 50 kDa isoform of SNX18 (Fig. 4B). The 74 kDa
band could not be detected here, possibly because it is ex-
pressed at lower levels than the 50 kDa SNX18-reactive band.
Our results suggest that the proline-rich domain of FasL inter-
acts directly with the SH3 domain of SNX18, and conﬁrm that
SNX18 can associate with wild-type FasL, as well as with
FasLD2–33.4. Discussion
In this report, we present the ﬁrst investigation of FasL
interacting proteins in cells of the nervous system. Our screen
identiﬁed four FasL interacting proteins, two previously
reported in T cells, PACSIN 2 and 3, and two novel FasL
interactors, SNX18 and adaptin b.
SNX18 represents a novel FasL interacting protein in Schw-
ann cells. Our antisera reacted with multiple bands present at
68–74 kDa as well as with a 50 kDa band, of which the bands
at 74 and 50 kDa co-precipitated with FasL (Figs. 4 and 5).
SNX18 is phosphorylated on serine and tyrosine residues
downstream of multiple receptor tyrosine kinases (JBC,
unpublished data), and these bands may correspond to diﬀer-
entially phosphorylated isoforms of SNX18. In support of this
hypothesis, phosphorylation of SNX9, the most closely related
member of the sorting nexin family, alters the cellular target of
its SH3 domain in vitro [20]. Our results suggest that SNX18
associates directly with the proline-rich domain of FasL via
its SH3 domain.
Although there are to date no published data on the cellular
functions of SNX18, insights into the potential consequences
of its association with FasL can be gleaned by comparison
with its closest homologue, SNX9. The domain architectures
of SNX9 and SNX18 are identical, and the molecules are-SH3 domain. (A) Peptides corresponding to FasL 1–12, 18–29, 33–44,
8 SH3 domain fused to GST (GST-SNX18SH3). Only peptides derived
) Lysates from Schwann cells transiently transfected with wild-type (wt)
tibodies and subjected to immunoblotting with antibodies to FasL and
18 co-precipitated with wt FasL (bottom arrow). Although the band at
emely low expression levels of wt FasL, also undetectable in the lysate
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identiﬁed as an interactor with two members of the A Disinte-
grin And Metalloprotease (ADAM) family, ADAMs 9 and 15
[21]. Interestingly, ADAM family members are the proteases
that mediate shedding of the FasL extracellular domain from
the cell surface to generate soluble FasL (sFasL) [22].
SNX18 associated with FasL may therefore recruit ADAMs
to FasL, promoting FasL shedding from the membrane. Fur-
thermore, SNX9, as well as SNX18, associate with the Ras
activating protein SOS [23], potentially linking FasL to the
ERK signaling pathway and providing a mechanism for FasL
reverse signaling via ERK. As in T cells, we also observe ERK
activation in Schwann cells upon stimulation of FasL with
agonistic antibodies or Fas fusion proteins (PBT, unpublished
data), suggesting that this pathway is conserved across cell
types. Finally, SNX9 also associates with the b2 adaptin sub-
unit of the AP-2 complex [24], stimulates the budding step of
endocytosis via activation of the GTPase activity of dynamin
[25], and participates in the activation-dependent degradation
of the epidermal growth factor receptor [26]. Therefore, it is
interesting to hypothesize that SNX18 may participate in the
downregulation of cell surface FasL either by facilitating its
internalization, or by promoting extracellular domain shed-
ding of the protein.
Our screen also identiﬁed b adaptin as a novel FasL interact-
ing protein. We detected b adaptin associated with wild-type
FasL, FasLD2–33, and FasLD2–70 in Schwann cells (Fig. 3).
Our data indicate that the 10 amino acids in the cytoplasmic
tail of FasL that are still present in FasLD2–70 are suﬃcient
to mediate the interaction between FasL and b adaptin, and
thus suggest a diﬀerent mode of association for the FasL–b
adaptin interaction than for the FasL–SNX18 interaction.
FasL does not contain YXXU or dileucine sorting signals
known to bind to the adaptor protein complexes, suggesting
that FasL may associate with b adaptin via a novel interaction
domain or indirectly via a third protein. The association of
FasL with b adaptin, whether direct or indirect, may be an
important regulator of the surface expression of the protein
and hence control both FasL forward (via Fas) and reverse sig-
naling.
Our screen further identiﬁed the PACSIN proteins 2 and 3
as FasL interacting proteins in Schwann cells, conﬁrming pre-
vious ﬁndings in T cells and suggesting that these interactions
are conserved in multiple cell types. The three known PACSIN
proteins all contain an SH3 domain and a coiled coil domain,
and are highly implicated in endocytosis. By binding the
Wiskott Aldrich syndrome protein (WASP), a potent activator
of actin nucleation, and the GTPase dynamin, they are
thought to link endocytosis to the actin cytoskeleton [27].
Based on colocalization data, these proteins may also partici-
pate in the lysosomal localization of FasL [28]. Similar to
the Sorting Nexins, PACSIN proteins also bind to members
of the ADAM metalloprotease family and regulate ectodo-
main shedding of the pro-heparin binding EGF-like growth
factor [29].
Several previous studies have used GST pulldowns to exam-
ine FasL protein interactions in T cells [6,7]. Most of the FasL
interacting proteins identiﬁed appeared to attenuate the cell
surface expression of FasL and/or alter its subcellular localiza-
tion [28,30–32], rather than participate in FasL reverse signal-
ing. This is consistent with reports documenting increased
expression of FasL at the cell surface upon deletion of its pro-line rich domain [10,32]. The presence of multiple FasL inter-
acting proteins in T cells, as well as in Schwann cells, with roles
in regulating its localization highlight the need for tight regu-
lation of the eﬀector and reverse signaling activities of FasL.
This stringent regulation of FasL surface expression makes
intuitive sense, given its role in apoptotic signaling. FasL re-
verse signaling, by contrast, is often cited as weak or modest.
Our screen may have missed potential reverse signaling eﬀec-
tors due to the deletion of FasL amino acids 2–33; however,
a previous report failed to identify binding partners for
GST-FasL2-29 [6]. Our screen may also have overlooked po-
tential human-speciﬁc FasL interacting proteins, as we overex-
pressed human FasL in murine Schwann cells. However, the
intracellular region of FasL is highly conserved across species,
minimizing this possibility. Our ﬁndings suggest that the
downstream molecular mediators of reverse signaling are not
constitutively associated with FasL, but likely are recruited
upon interaction with Fas. Interestingly, molecules primarily
implicated in traﬃcking may also recruit signaling molecules
to the FasL complex, and therefore serve as upstream adaptor
proteins for reverse signaling. This may be the case for SNX18,
which could regulate FasL traﬃcking and also participate in
signaling by recruiting SOS to the complex upon Fas binding,
thereby activating the canonical ERK pathway.
In summary, our screen for FasL interacting proteins within
Schwann cells has identiﬁed two novel proteins, and conﬁrmed
two known FasL interactors, all with potential functions in
regulating traﬃcking and subcellular localization. Identiﬁca-
tion of these novel FasL interactors provides insight into
potential molecular mechanisms underlying this stringent reg-
ulation of cell surface FasL. In particular, our ﬁndings suggest
that multiple FasL interacting proteins, including the
PACSINs and SNX18, could link the export pathways of FasL
directly to its cleavage by ADAMs at the cell surface.
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